Brokerages Set Illumina, Inc. (NASDAQ:ILMN) Price Target at $159.45

Illumina, Inc. (NASDAQ:ILMN) has earned an average recommendation of “Moderate Buy” from the twenty-one brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $159.45.

Several equities research analysts recently issued reports on the stock. Canaccord Genuity Group dropped their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, February 7th. Stephens raised their price objective on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Morgan Stanley decreased their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. JPMorgan Chase & Co. raised their price objective on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Robert W. Baird raised their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th.

Institutional Trading of Illumina

Several hedge funds have recently bought and sold shares of ILMN. CX Institutional bought a new stake in Illumina in the 3rd quarter valued at about $218,000. Creative Planning lifted its position in Illumina by 3.3% in the 3rd quarter. Creative Planning now owns 16,679 shares of the life sciences company’s stock valued at $2,175,000 after purchasing an additional 535 shares during the last quarter. Beech Hill Advisors Inc. raised its position in shares of Illumina by 30.2% during the 3rd quarter. Beech Hill Advisors Inc. now owns 7,699 shares of the life sciences company’s stock worth $1,004,000 after buying an additional 1,784 shares in the last quarter. Probity Advisors Inc. bought a new stake in shares of Illumina during the 3rd quarter worth about $239,000. Finally, nVerses Capital LLC bought a new stake in shares of Illumina during the 3rd quarter worth about $65,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Performance

Illumina stock opened at $101.05 on Friday. Illumina has a 12-month low of $99.33 and a 12-month high of $156.66. The company has a market capitalization of $16.03 billion, a price-to-earnings ratio of -13.16 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The firm’s fifty day moving average price is $131.80 and its 200 day moving average price is $134.75.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. On average, research analysts forecast that Illumina will post 4.42 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.